辉瑞公司宣布劳拉替尼(lorlatinib,PF-06463922)的Ⅰ/Ⅱ期临床试验的新数据。该药是新一代ALK/ROS1酪氨酸激酶抑制剂。研究显示,ALK或ROS1阳性的晚期非小细胞肺癌患者,包括脑转移者,对该药有临床治疗反应。此资料已在52届美国临床肿瘤学协会年会上发表。Ⅰ期临床试验中患者未用药治疗或使用过≥1种酪氨酸激酶抑制剂而病情加重者经该药剂量递增治疗后,总有效反应率46%(3名完全有效,16名 Pfizer announces new data on stage I / II clinical trials of lorlatinib (PF-06463922). This drug is a new generation of ALK / ROS1 tyrosine kinase inhibitors. Studies have shown that ALK or ROS1-positive patients with advanced non-small cell lung cancer, including brain metastases, have a clinical response to the drug. This information has been published in the 52nd annual meeting of the American Society of Clinical Oncology. Phase I clinical trials in patients with no medication or the use of ≥ 1 tyrosine kinase inhibitors and exacerbations by the drug dose treatment, the total effective response rate of 46% (3 fully valid, 16